The Florida Hospital for Children in Orlando and Cord Blood Registry (CBR), headquartered in San Bruno, California, have recently launched a FDA-regulated clinical trial to study the use of a child’s own cord blood stem cells as a potential treatment for hearing loss.
Headed by James Baumgartner, MD, surgical director of Florida Hospital for Children's Comprehensive Pediatric Epilepsy Center in Orlando, the trial exclusively involves patients who have saved their child's cord blood stem cells with CBR.
Approximately 15% of American children experience hearing loss. For some, it’s genetic; three out of every 1,000 babies are born with a genetic hearing problem. For others, it’s developed. Sensorineural hearing loss, the most common type of hearing loss, results from damage to hair cells in the inner ear caused by illness, excessive noise exposure, some medications, or physical trauma.
The study will work to test if cord blood stem cells can be used to trigger the body’s own repair mechanisms to restore the hair cells and a child’s hearing ability.
The study is currently enrolling children ages 6 weeks to 6 years with acquired hearing loss.
To learn more, click here.
Last updated: February 25, 2014